GLUE

Companies
NASDAQ
Monte Rosa Therapeutics Inc.
Health Care
Price Chart
Overview

About GLUE

small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.

Market Cap
$243.4M
Volume
3.4M
Avg. Volume
3.5M
P/E Ratio
-2.7033331
Dividend Yield
0.00%
Employees
128.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.30
High Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for GLUE.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, GLUE shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$243.4M
Volume3.4M
P/E Ratio-2.70
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 14, 2024
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how GLUE fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025